Focused On-demand Library for Ubiquinone biosynthesis monooxygenase COQ6, mitochondrial

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.

Several key aspects differentiate our library:

  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.







Alternative names:

Coenzyme Q10 monooxygenase 6

Alternative UPACC:

Q9Y2Z9; B7Z3K8; Q53GG6; Q86U30; Q96CA1; Q96CK2


Ubiquinone biosynthesis monooxygenase COQ6, mitochondrial, also known as Coenzyme Q10 monooxygenase 6, plays a crucial role in the biosynthesis of ubiquinone, a vital component in the mitochondrial electron transport chain. This enzyme specifically catalyzes the hydroxylation of 3-hexaprenyl-4-hydroxybenzoic acid, a key step in coenzyme Q10 production.

Therapeutic significance:

Mutations in COQ6 have been linked to Coenzyme Q10 deficiency, primary, 6, a severe disorder leading to progressive nephrotic syndrome and sensorineural deafness. Understanding the role of Ubiquinone biosynthesis monooxygenase COQ6 could open doors to potential therapeutic strategies for this debilitating condition.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.